We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Gene Therapy for Pyruvate Kinase Deficiency (PKD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04105166
Recruitment Status : Recruiting
First Posted : September 26, 2019
Last Update Posted : September 24, 2021
Information provided by (Responsible Party):
Rocket Pharmaceuticals Inc.

Brief Summary:
This is an open-label Phase I trial to evaluate the safety of a hematopoietic cell-based gene therapy for patients with Pyruvate Kinase Deficiency (PKD).

Condition or disease Intervention/treatment Phase
Pyruvate Kinase Deficiency Biological: RP-L301 Phase 1

Detailed Description:
Autologous hematopoietic stem cells from mobilized peripheral blood will be transduced ex vivo (outside the body) with a lentiviral vector carrying a correct copy of the deficient PKD gene. The corrected stem cells will be infused intravenously back to the patient with the goal of correcting the hematological manifestations of the disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: Initial safety evaluation will occur in an adult cohort (n=2) patients, followed by pediatric patients ages 12-17 (n=2), and pediatric patients ages 8-11 (n=2).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Adult and Pediatric Subjects With PKD
Actual Study Start Date : July 6, 2020
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023

Arm Intervention/treatment
Experimental: RP-L301
RP-L301 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
Biological: RP-L301
Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene

Primary Outcome Measures :
  1. Evaluation of the safety and toxicity of RP-L301: number of participants with treatment-related adverse events [ Time Frame: 2 years ]
    The number of participants with treatment-related adverse events as assessed by United States (US) National Cancer Institute (NCI) v.5.0.

Secondary Outcome Measures :
  1. Genetic correction following administration of RP-L301 [ Time Frame: 2 years ]
    Evidence of mult-lineage gene correction in peripheral blood (PB) and bone marrow (BM cells) will be assessed by measuring vector copy number

  2. Transfusion independence [ Time Frame: 1 year ]
    Transfusion independence (when relevant) at 12 months defined as need for less than or equal to 1 red blood cell transfusion in the previous 6 months

  3. Reduction in transfusion requirements [ Time Frame: 1 year ]
    50% reduction in transfusion requirements (when relevant) at 12 months (assessed in the previous 6 months for the 12-month assessment) relative to the 1-year period prior to enrollment

  4. Clinically significant reduction in anemia [ Time Frame: 2 years ]

    Increase in pre-transfusion hemoglobin (Hb) levels of 1.5 g/dL (determined by 2 assessments separated at least three months over the first and second year of follow up) relative to the average of patient's Hb levels before blood transfusions over the year prior to enrollment OR

    Increase of at least two-fold in the time to pre-transfusion Hb nadir relative to the average transfusion interval over the year prior to enrollment, where pre-transfusion Hb nadir is defined as the average Hb value (during the year prior to enrollment) prior to red blood cell (RBC) transfusions

  5. Reduction of hemolysis [ Time Frame: 1 year ]
    Reduction of reticulocytosis, defined as the number of patients with a reduction of 50% from the average of a patient's absolute reticulocyte counts (obtained prior to therapeutic blood transfusions) over the year prior to enrollment at 12 months subsequent to investigational therapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • PKD diagnosis with a confirmed PKLR mutation.
  • Age ≥18 years old and <50 years for the initial 2 patients enrolled; ≥12-17 years for the next 2 patients; ≥8-11 years for the final 2 patients.
  • History of severe, transfusion-dependent anemia, defined as:

    1. At least 6 red blood cell transfusion episodes over a prior 12-month period, or at least 3 red blood cell transfusion episodes per year over 2 prior years (in the absence of precipitating events such as infection or surgery) and
    2. Hb levels <9.5 g/dL in the previous 12 months despite prior splenectomy. OR for adult patients (age ≥ 18 years) and older pediatric patients (age 12-17)
    3. Hb levels <8.0 g/dL in the absence of transfusions (documented during 2 or more assessments during the prior 1-2 years) regardless of transfusion requirements.
  • Adequate cardiac, pulmonary, renal and hepatic function, as detailed in relevant exclusion criteria.
  • Availability of detailed medical records, including transfusion requirements, for at least the prior 2 years.
  • Willing and able to read and correctly understand the patient information sheet and provide consent (or informed assent for minors) regarding study participation.
  • Negative serum pregnancy test for female patients of childbearing potential.

Exclusion Criteria:

  • Presence of other known causes of hemolysis (in addition to PKD). Patients with concurrent G6PD deficiency diagnosed during pre-study evaluation may be considered for eligibility if in the opinion of the Investigator, the hemolytic anemia is the result of PKD and the G6PD deficiency is considered an incidental finding.
  • A venous thromboembolic event (VTE; i.e., pulmonary embolism or deep vein thrombosis) or arteriothromboembolic event (ATE; including unstable angina, myocardial infarction, stroke or transient ischemic attack) during the prior 12 months.
  • Any evidence of severe iron overload that, per Investigator discretion, warrants exclusion.
  • Evidence of bridging fibrosis, cirrhosis or active hepatitis on liver biopsy. Liver biopsy is required when liver iron concentration (LIC) is ≥15 mg/g on T2* magnetic resonance imaging (MRI) of liver. If a liver biopsy has been performed less than 6 months prior to enrollment, it does not need to be repeated.
  • Significant medical conditions including documented HIV infection, active viral hepatitis, poorly-controlled hypertension, pulmonary hypertension cardiac arrhythmia or congestive heart failure; pulmonary hypertension or ATEs (including stroke or myocardial infarction) within the 6 prior months.
  • Active hematologic or solid organ malignancy, not including non-melanoma skin cancer or another carcinoma in situ. Patients with previously resected solid organ malignancies or definitively treated hematologic malignancies may be eligible if there has been no evidence of active malignancy during the prior 3 years.
  • Uncontrolled seizure disorder.
  • Cardiac T2*<10 ms by magnetic resonance imaging (MRI) or left ventricular ejection fraction (LVEF) <45% by echocardiogram or multiple gated acquisition (MUGA) scanning.
  • Hepatic dysfunction as defined by: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5× the upper limit of normal.(ULN).
  • Renal dysfunction as defined as serum creatinine > ULN. Patients with creatinine above ULN may be eligible pending documentation of a GFR ≥60 mL/min/1.73m2 as calculated by the Modification of Diet in Renal Disease equation (Stevens 2006), the revised Schwartz formula (for patients under 18 years old) (Schwartz 2009), or 24-hour urine collection.
  • Pulmonary dysfunction as defined by either:

    • Need for supplemental oxygen during the prior 2 weeks (in absence of acute infection) or
    • Oxygen saturation (by pulse oximetry) <90%.
  • Any medical or other contraindication for both leukapheresis and BM harvest procedure as determined by the treating Investigator.
  • Any medical or psychiatric condition that in the opinion of the Investigator renders the subject unfit for trial participation or at higher than acceptable risk for participation.
  • Poor functional status, evidenced by Karnofsky Index <70 in adults or Lansky <70 in children.
  • Participation in another clinical trial with an investigational drug within 14 days before the informed consent signature. Participation in observational studies is allowed.
  • Pregnant women or women with a positive serum pregnancy test at screening or breast feeding or planning to become pregnant within the next 24 months. Women not willing to use highly effective contraceptive methods during the complete study period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04105166

Layout table for location contacts
Contact: Clinical Information 646-627-0033 PKDclinicaltrial@rocketpharma.com
Contact: PKD Clinical Trial PKDclinicaltrial@rocketpharma.com

Layout table for location information
United States, California
Stanford University Recruiting
Stanford, California, United States, 94304
Contact: Elisabeth Merkel       scgt_clinical_trials_office@lists.stanford.edu   
Hospital Infantil Universitario Niño Jesús Recruiting
Madrid, Spain, 28009
Contact: Julián Sevilla Navarro, MD, PhD    +34 91 503 59 00 ext 480    julian.sevilla@salud.madrid.org   
Hospital Universitario Fundación Jiménez Díaz Recruiting
Madrid, Spain
Contact: José Luis López Lorenzo, MD    +34 91 550 48 00 ext 2870    JLLopez@quironsalud.es   
Sponsors and Collaborators
Rocket Pharmaceuticals Inc.
Layout table for investigator information
Principal Investigator: José Luis López Lorenzo, MD Hospital Universitario Fundación Jiménez Díaz
Principal Investigator: Ami Shah, MD Stanford University
Principal Investigator: Julián Sevilla Navarro, MD, PhD Hospital Universitario Fundación Jiménez Díaz
Layout table for additonal information
Responsible Party: Rocket Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT04105166    
Other Study ID Numbers: RP-L301-0119
First Posted: September 26, 2019    Key Record Dates
Last Update Posted: September 24, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Rocket Pharmaceuticals Inc.:
hemolytic anemia
gene therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Hemolytic, Congenital Nonspherocytic
Pyruvate Metabolism, Inborn Errors
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Metabolic Diseases